BMO Capital Initiates Coverage on Tetraphase Pharmaceuticals Inc(NASDAQ:TTPH). The shares have been rated Market Perform. The rating by BMO Capital was issued on Apr 12, 2016.
Tetraphase Pharmaceuticals Inc (TTPH) made into the market gainers list on Fridays trading session with the shares advancing 0.56% or 0.03 points. Due to strong positive momentum, the stock ended at $5.35, which is also near the day’s high of $5.41. The stock began the session at $5.29 and the volume stood at 6,55,054 shares. The 52-week high of the shares is $52.9 and the 52 week low is $3.48. The company has a current market capitalization of $196 M and it has 3,65,99,227 shares in outstanding.
Tetraphase Pharmaceuticals Inc(TTPH) last announced its earnings results on Feb 23, 2016 for Fiscal Year 2015 and Q4.Earnings per share were $-0.50.
Several Insider Transactions has been reported to the SEC. On Sep 10, 2015, John Craig Thompson (Chief Operating Officer) sold 10,000 shares at $44.08 per share price.Also, On Sep 3, 2015, Guy Macdonald (President and Chief Executive) sold 10,000 shares at $41.57 per share price.On Aug 17, 2015, David Charles Lubner (SVP and CFO) sold 9,500 shares at $42.92 per share price, according to the Form-4 filing with the securities and exchange commission.
Tetraphase Pharmaceuticals Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. The Company is engaged in developing its product candidate eravacycline which is a fully synthetic tetracycline derivative as a spectrum intravenous (IV) and an oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections including multidrug-resistant Gram-negative infections. TP-271 is a fully synthetic broad-spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271 the Company has conducted a number of in vitro toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens.